Titan Pharmaceuticals (NASDAQ:TTNP) has received funding from the Bill & Melinda Gates Foundation to support its ability to deliver a human immunodeficiency virus (HIV) preventative therapeutic and a contraceptive from a single implant for women in developing countries using its proprietary ProNeura technology.
“Reducing the burden of HIV, while simultaneously increasing access to contraceptive options, could have a major impact on the health of women and adolescent girls in low- and middle-income countries,” Marc Rubin, M.D., executive chairman of Titan, said in a statement.
“We believe that our ProNeura platform is uniquely suited to this program, as we have demonstrated the feasibility of long-term delivery of two pharmaceutically active ingredients from a single implant in an earlier development program,” he added.
Dr. Rubin said the continuous long-term delivery of a contraceptive/antiviral combination has the potential to have a greater public health impact in developing nations, compared with daily dosing of multiple compounds.
